HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Panel Sets Plan For Tackling Ingredients’ Inhalation Toxicity Data

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel decided Sept. 27 to assess the respiratory and inhalation toxicity of ingredients used in personal-care products intended to be sprayed.

You may also be interested in...



CIR Director Gill Steps Down, Leaving Legacy Of Improved Transparency

Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.

Gill To Take CIR Director Role With Andersen’s Exit

CIR Deputy Director Lillian Gill will replace Alan Andersen as director this summer, the group reported at its March 18-19 meeting. Gill was chosen because of her “hard-nosed” approach to regulation, says Andersen, who added that he will be available for some time as a consultant.

FDA: No Asbestos Found In Talc Products Sampled, But Results Limited

Following reports of asbestos in talc and talc-containing products overseas, FDA conducted a survey of suppliers and products on the U.S. market, finding no detectable levels of asbestos.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel